compounded glp-1 medications Hims Inc Despite FDA ruling, compounded GLP-1s

Novo Nordisks acquisition of Catalent manufacturing facilities, valued at approximately US$11 billion, highlights the importance of production capacity in the GLP-1 market

The GLP-1 medications, such as semaglutide and tirzepatide have spearheaded the trend

In recent weeks, Novo Nordisks commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients

Holscher, C

increasing from about 31% in 1999 to roughly 42% in 2023

This article explains the gastrointestinal effects of GLP-1 therapy and provides practical guidance for managing bowel changes during treatment